Abstract: Certain aspects of the present disclosure are directed to a video processing module, including: a video capture module configured to capture a screen display; a compression module configured to compress the screen display to construct compressed data representing the screen display; and a memory module configured to store the compressed data. Certain aspects are directed to a computer-implementable method, including: reading compressed video data having a plurality of data units and representing a screen display out of a data storage, the data units including a line tag, an encoding tag, and a pixel value data unit; detecting a line tag from the compressed video data and extracting a line number from the line tag; receiving an expected line number from a counter; comparing the line number with the expected line number and determining a comparison result; and determining whether a fault exists based on the result.

Abstract: This invention describes the use of anti-IL-1 antibody as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the anti-IL-1 antibody coated liposomes. The anti-IL-1 antibody coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with anti-IL-1 antibody and used to deliver the drug to the site of inflammation. Also in lieu of the anti-IL-1 antibody other IL-1 binding agents such as anti-IL-1 aptamers and anti-IL-1 binding peptides may be used to coat various nanosized drug delivery vehicles in order to deliver the drug to the site of inflammation.

Abstract: This invention describes the use of anti-TNF-a antibody as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the anti-TNF-a coated liposomes. The anti-TNF-a coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with anti-TNF-a antibody and used to deliver the drug to the site of inflammation. Also in lieu of the anti-TNF-a antibody other TNF-a binding agents such as aptamers and binding peptides may be used to coat the various nanosized drug delivery vehicles such as micelles, dendrimers, nanocapsules and nanoparticles in order to deliver the drug to the site of inflammation.

Abstract: This invention describes the use of sTNF-R as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the sTNF-R coated liposomes. The sTNF-R coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with sTNF-R and used to deliver the drug to the site of inflammation.

Abstract: This invention uses “Targeted Apheresis” to treat patients with Rheumatoid Arthritis and other autoimmune and inflammatory disorders. “Targeted Apheresis” is a process whereby only the pathogenic and pro-inflammatory elements associated with the disease symptoms are simultaneously and selectively removed from the blood by passing the blood through an extracorporeal affinity device containing selective binding agents. Removal of these pathogenic and pro-inflammatory elements will ameliorate the symptoms of autoimmune disease and may prolong the period of disease remission.

Abstract: Techniques for determining conditions of power lines in a power distribution system based on data collected by a plurality of sensor units deployed in the power distribution system. The techniques include obtaining data associated with measurements collected by at least two sensor units in the plurality of sensor units, and determining, by using at least one processor, at least one condition of at least one power line in the power distribution system by using the data obtained by the at least two sensor units.

Abstract: Techniques for determining conditions of power lines in a power distribution system based on measurements collected by a plurality of sensor units deployed in the power distribution system. Techniques include obtaining first transformed data associated with a first set of one or more measurements collected by a first sensor unit in the plurality of sensor units and second transformed data associated with a second set of one or more measurements collected by a second sensor unit in the plurality of sensor units, and determining, by using at least one processor and based at least in part on one or more features calculated from the first transformed data and the second transformed data, at least one condition of at least one power line in the power distribution system.

Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: A process for treating tumors by administering a mixture of cancer fighting drugs incorporated into a stabilized liposomal formulation. Each cancer drug is selected to target a different phase of the cell-cycle of the cancer cell thus expanding the number of cancer cells that can be killed at one time without compromising the safety of the patient. The stabilized multi-drug liposomes are designed to extravasate thru “leaky” blood capillaries supplying the tumor and enter the tumor tissue where they will accumulate over time and ultimately released to kill surrounding tumor cells. The multi-drug liposomes are likewise unable to extravasate thru normal blood capillaries and will thus be less toxic to normal tissues.

Abstract: This invention uses “targeted apheresis” to treat pregnant women who are at risk of developing eclampsia. “Targeted Apheresis” is a process whereby certain growth factor receptors (sFlt-1) circulating in the blood of a pregnant woman at risk of developing pre-eclampsia are selectively removed by passing the blood through a cartridge containing immobilized anti-sFlt-1 aptamers. The circulating sFlt-1 is bound out by the immobilized anti-sFlt-1 aptamers and the cleaned blood is returned to the patient. Removal of circulating sFlt-1 will diminish the risk of developing eclampsia during pregnancy.

Abstract: A basket processing apparatus that includes a basket storage portion in a form of a horizontal load rail. A plurality of slide storage baskets can be located in series on the rail. Each basket is ‘side loading’ and the side loading aperture of each basket can be selectively covered by a slide retaining bar. When the baskets are placed on the load rail, the basket can be moved along the horizontal rail by a basket moving means. The arrangement of the rail and the basket moving means is such that the baskets can be pushed together and move as a ‘train’. Baskets moved to the pick-up end of the rail can then be removed from the rail and processed. A vertical lift mechanism can be used to remove the basket and transport it to a processing device, for example a coverslipper.

Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Abstract: A support for electrical cables having a nonconductive telescoping pole. A frictional locking collar couples sections of the telescoping pole to one another. The bottom end of the pole fits into a round conical base formed of recycled tires. The top end of the pole is affixed to a nonconductive head that is shaped to cradle electrical cables.

Abstract: The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I).

Abstract: The invention relates to novel heterocycles of formula (I) processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.

Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.

Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.